Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 4/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL283516 | 0.79 | — | — | |
| SCHEMBL17351504 | 0.75 | MCL1 (0.37) | MCL1KMT2A | |
| SCHEMBL18692589 | 0.75 | MCL1 (0.37) | MCL1KMT2A | |
| SCHEMBL16866560 | 0.73 | MCL1 (0.35) | MCL1KMT2A | |
| SCHEMBL16541488 | 0.73 | DPP4 (0.37) | MCL1KMT2ACTSK | |
| SCHEMBL1255072 | 0.73 | MCL1 (0.35) | MCL1KMT2A | |
| SCHEMBL371371 | 0.73 | DPP4 (0.37) | MCL1KMT2ACTSK | |
| SCHEMBL24410548 | 0.71 | MCL1 (0.36) | MCL1KMT2A | |
| SCHEMBL23982435 | 0.71 | PKM (0.41) | MCL1KMT2A | |
| Acetonitrile SCHEMBL25261563 | 0.71 | MCL1 (0.33) | MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4240738-B1 | PYRAZOLE DERIVATIVES AS RET KINASE INHIBITORS | LILLY CO ELI (US) | 2025-05-07 | — | — | EP | disclosed |
| US-11970485-B2 | RET kinase inhibitors | ELI LILLY AND COMPANY (US) | 2024-04-30 | — | — | US | disclosed |
| US-20230265085-A1 | RET KINASE INHIBITORS | LOXO ONCOLOGY, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230265085-A1 | RET KINASE INHIBITORS | LOXO ONCOLOGY, INC. | 2023-08-24 | — | — | US | disclosed |
| US-11697647-B2 | RET kinase inhibitors | ELI LILLY AND COMPANY (US) | 2023-07-11 | — | — | US | disclosed |
| US-11697647-B2 | RET kinase inhibitors | ELI LILLY AND COMPANY (US) | 2023-07-11 | — | — | US | disclosed |
| WO-2022098970-A9 | PYRAZOLE DERIVATIVES AS RET KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2023-04-27 | — | — | WO | disclosed |
| WO-2022098970-A1 | PYRAZOLE DERIVATIVES ASR ET KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2022-05-12 | — | — | WO | disclosed |
| US-20220144816-A1 | RET KINASE INHIBITORS | EVOTEC INTERNATIONAL GMBH (DE) | 2022-05-12 | — | — | US | disclosed |
| US-20220144816-A1 | RET KINASE INHIBITORS | EVOTEC INTERNATIONAL GMBH (DE) | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11970485-B2 | RET kinase inhibitors | RET, BRAF, GFRA1 | MCL1 851/4885RIPK1 378/4885KMT2A 790/4885 |
| US-11697647-B2 | RET kinase inhibitors | RET, BRAF, GFRA1 | MCL1 851/4885RIPK1 378/4885KMT2A 790/4885 |
| US-20230265085-A1 | RET KINASE INHIBITORS | RET, BRAF, GFRA1 | MCL1 851/4885RIPK1 378/4885KMT2A 790/4885 |
| US-20220144816-A1 | RET KINASE INHIBITORS | RET, BRAF, GFRA1 | MCL1 851/4885RIPK1 378/4885KMT2A 790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.